Picture2

The efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA)

A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA)

Principal Investigator: